Christina Wang

TL;DR: The peak luteinizing hormone and follicle‐stimulating hormone responses to intravenous lute inizing hormone‐releasing hormone were reduced significantly 4 weeks after starting treatment and remained suppressed while the patients were on treatment.

TL;DR: A coordinated set of clinical trials designed to avoid the pitfalls of prior studies and to determine definitively whether testosterone treatment of elderly men with low testosterone is efficacious in improving symptoms and objec- tive measures of age-associated conditions is presented.

TL;DR: Current male-controlled methods are limited to coitus interruptus, male condoms, and vasectomy, while new female methods under preclinical or early clinical development include immunocontraception using antisperm antibodies, anti-zona-pellucida antibodies, or anti-hCG vaccine; new injectable progesterone esters; and new vaginal spermicides with antiviral activities that will provide dual protection.